Moreover, high circulating levels of adiponectin are associated with decreased risk of myocardial infarction, independent of other factors.
Adiponectin has the potential to become a clinically relevant parameter to be measured routinely in subjects at risk for type 2 diabetes, atherosclerosis and the metabolic syndrome.